Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Pharmacology and Experimental Therapeutics
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Journal of Pharmacology and Experimental Therapeutics

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit jpet on Facebook
  • Follow jpet on Twitter
  • Follow jpet on LinkedIn
OtherIMMUNOPHARMACOLOGY

The Role of Platelet-Activating Factor (PAF) and the Efficacy of ABT-491, a Highly Potent and Selective PAF Antagonist, in Experimental Allergic Rhinitis

Daniel H. Albert, Peter E. Malo, Paul Tapang, Thomas K. Shaughnessy, Douglas W. Morgan, Craig D. Wegner, Michael L. Curtin, George S. Sheppard, Lianhong Xu, Steven K. Davidsen, James B. Summers and George W. Carter
Journal of Pharmacology and Experimental Therapeutics January 1998, 284 (1) 83-88;
Daniel H. Albert
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Peter E. Malo
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Paul Tapang
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Thomas K. Shaughnessy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Douglas W. Morgan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Craig D. Wegner
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michael L. Curtin
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
George S. Sheppard
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lianhong Xu
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Steven K. Davidsen
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
James B. Summers
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
George W. Carter
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

Platelet-activating factor (PAF) may be an important mediator of allergic rhinitis. In the present study we evaluated the effectiveness of a recently described PAF antagonist (ABT-491) in rat and guinea pig models of allergic rhinitis. PAF, when perfused through the nasal passages of anesthetized Brown Norway rats, provoked an acute increase, measured as dye leakage, in nasal vascular permeability evident within 15 min after exposure to PAF. ABT-491, given orally 1 hr before PAF challenge, inhibited the response in a dose-related manner (ED50 = 0.3 mg/kg). Intranasal perfusion with ovalbumin in rats sensitized to the antigen 18 to 21 days before challenge also induced an increase in vascular permeability. The antigen-induced leakage was inhibited a maximum of 74% (P ≤ .001) by pretreatment with ABT-491 (3 mg/kg p.o.). An antihistamine (mepyramine, 10 mg/kg i.p.), a serotonin antagonist (methysergide) and a 5-lipoxygenase inhibitor (A-79175) also exhibited efficacy in this model (56%, 87% and 65% inhibition, respectively). Nearly complete inhibition (93%, P ≤ .001) of the response was achieved by coadministration of ABT-491 and methysergide. In guinea pigs intranasal administration of PAF resulted in increased airway resistance that was inhibited in a dose-dependent manner by oral administration of ABT-491 (ED50 = 1 mg/kg). Antigen-induced nasal airway resistance, triggered by exposure of sensitized animals to aerosolized ovalbumin, was also inhibited by ABT-491 (maximum inhibition 64%, P ≤ .05, 10 mg/kg p.o.). The effectiveness of the antagonist was increased to 80% protection by coadministration with either an antihistamine or a 5-lipoxygenase inhibitor, agents which were separately insignificant in blocking the response to antigen. These results suggest a therapeutic utility for ABT-491, perhaps in combination with other anti-inflammatory agents, in the treatment of allergic rhinitis.

Footnotes

  • Send reprint requests to: Daniel H. Albert, Dept. 47J, Bldg. AP9, 100 Abbott Park Road, Abbott Laboratories, Abbott Park, IL 60064-3500.

  • Abbreviations:
    PAF
    platelet-activating factor
    OA
    ovalbumin
    BSA
    bovine serum albumin
    • Received May 21, 1997.
    • Accepted September 22, 1997.
  • The American Society for Pharmacology and Experimental Therapeutics
View Full Text

JPET articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top

In this issue

Journal of Pharmacology and Experimental Therapeutics
Vol. 284, Issue 1
1 Jan 1998
  • Table of Contents
  • Index by author
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Journal of Pharmacology and Experimental Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
The Role of Platelet-Activating Factor (PAF) and the Efficacy of ABT-491, a Highly Potent and Selective PAF Antagonist, in Experimental Allergic Rhinitis
(Your Name) has forwarded a page to you from Journal of Pharmacology and Experimental Therapeutics
(Your Name) thought you would be interested in this article in Journal of Pharmacology and Experimental Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
OtherIMMUNOPHARMACOLOGY

The Role of Platelet-Activating Factor (PAF) and the Efficacy of ABT-491, a Highly Potent and Selective PAF Antagonist, in Experimental Allergic Rhinitis

Daniel H. Albert, Peter E. Malo, Paul Tapang, Thomas K. Shaughnessy, Douglas W. Morgan, Craig D. Wegner, Michael L. Curtin, George S. Sheppard, Lianhong Xu, Steven K. Davidsen, James B. Summers and George W. Carter
Journal of Pharmacology and Experimental Therapeutics January 1, 1998, 284 (1) 83-88;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
OtherIMMUNOPHARMACOLOGY

The Role of Platelet-Activating Factor (PAF) and the Efficacy of ABT-491, a Highly Potent and Selective PAF Antagonist, in Experimental Allergic Rhinitis

Daniel H. Albert, Peter E. Malo, Paul Tapang, Thomas K. Shaughnessy, Douglas W. Morgan, Craig D. Wegner, Michael L. Curtin, George S. Sheppard, Lianhong Xu, Steven K. Davidsen, James B. Summers and George W. Carter
Journal of Pharmacology and Experimental Therapeutics January 1, 1998, 284 (1) 83-88;
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Modulation of Mouse Endotoxin Shock by Inhibition of Phosphatidylcholine-Specific Phospholipase C
  • IL-10 Synergizes with Dexamethasone in Inhibiting Human T Cell Proliferation
  • Spontaneous and Cationic Lipid-Mediated Uptake of Antisense Oligonucleotides in Human Monocytes and Lymphocytes
Show more IMMUNOPHARMACOLOGY

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About JPET
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0103 (Online)

Copyright © 2023 by the American Society for Pharmacology and Experimental Therapeutics